General Information of Drug Therapeutic Target (DTT) (ID: TTH029C)

DTT Name Retinoic acid receptor RXR-gamma (RXRG)
Synonyms Retinoid X receptor gamma; Nuclear receptor subfamily 2 group B member 3; NR2B3
Gene Name RXRG
DTT Type
Successful target
[1]
BioChemical Class
Nuclear hormone receptor
UniProt ID
RXRG_HUMAN
TTD ID
T46456
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MYGNYSHFMKFPAGYGGSPGHTGSTSMSPSAALSTGKPMDSHPSYTDTPVSAPRTLSAVG
TPLNALGSPYRVITSAMGPPSGALAAPPGINLVAPPSSQLNVVNSVSSSEDIKPLPGLPG
IGNMNYPSTSPGSLVKHICAICGDRSSGKHYGVYSCEGCKGFFKRTIRKDLIYTCRDNKD
CLIDKRQRNRCQYCRYQKCLVMGMKREAVQEERQRSRERAESEAECATSGHEDMPVERIL
EAELAVEPKTESYGDMNMENSTNDPVTNICHAADKQLFTLVEWAKRIPHFSDLTLEDQVI
LLRAGWNELLIASFSHRSVSVQDGILLATGLHVHRSSAHSAGVGSIFDRVLTELVSKMKD
MQMDKSELGCLRAIVLFNPDAKGLSNPSEVETLREKVYATLEAYTKQKYPEQPGRFAKLL
LRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLETPLQIT
Function
Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. Receptor for retinoic acid.
KEGG Pathway
PPAR signaling pathway (hsa03320 )
Thyroid hormone signaling pathway (hsa04919 )
Adipocytokine signaling pathway (hsa04920 )
Pathways in cancer (hsa05200 )
Transcriptional misregulation in cancer (hsa05202 )
Thyroid cancer (hsa05216 )
Small cell lung cancer (hsa05222 )
Non-small cell lung cancer (hsa05223 )
Reactome Pathway
Nuclear Receptor transcription pathway (R-HSA-383280 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [2]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [1]
------------------------------------------------------------------------------------
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
NRX-4204 DMYXOU2 Diabetic complication 5A2Y Phase 2 [3]
9cUAB-30 DMYKPXJ Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
IRX4204 DM9SCME Breast cancer 2C60-2C65 Phase 1 [5]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
SR-11237 DMQG3CK Solid tumour/cancer 2A00-2F9Z Terminated [6]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AGN-34 DM5ECDM Discovery agent N.A. Investigative [7]
LG100754 DMEK4FY Discovery agent N.A. Investigative [8]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Prostate cancer 2C82 Prostate 4.44E-02 -0.25 -0.41
------------------------------------------------------------------------------------

References

1 Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
2 Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
3 DOI: 10.1038/scibx.2010.766
4 In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64.
5 Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Oncotarget.2016 Feb 16;7(7):7469-79.
6 Silicon analogues of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology. ChemMedChem. 2009 Jul;4(7):1143-52.
7 Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403.
8 Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 1996 Oct 3;383(6599):450-3.